Camurus Investor Relations Material

Camurus is a pharmaceutical company that develops and commercializes long-acting treatments for serious and chronic conditions. The company specializes in proprietary drug delivery technologies, particularly its FluidCrystal system, which is designed to provide extended drug release through subcutaneous or intramuscular injection. Camurus focuses on areas such as opioid dependence, pain management, oncology, and endocrinology, aiming to improve treatment adherence and patient outcomes. Its product portfolio includes both commercialized therapies and development-stage programs across multiple therapeutic areas. The company is headquartered in Lund, Sweden, and its shares are listed on the Stockholm Stock Exchange.